Human Papillomavirus Testing Market – Overview
The global human papillomavirus testing market is projected to rise at a healthy rate from 2021 to 2031 (forecast period). The increased global prevalence of cervical cancer is a major factor projected to drive the global human papillomavirus testing market during the forecast period. As per the World Health Organization, cervical cancer is the fourth most frequent cancer in women, accounting for 6.6% of all female cancers. Roughly 90% of cervical cancer deaths occur in the middle- to low-income nations.
Furthermore, as per the American Cancer Society, 13,170 new instances of invasive cervical cancer were diagnosed, and 4,250 deaths occurred from cervical cancer in the United States in 2019. As a result, the rising number of cervical cancer cases worldwide is projected to propel the global human papillomavirus testing market.
Expanding operations in future? To get the perfect launch ask for a custom report
Human Papillomavirus Testing Market – Competitive Landscape
Key players in the global human papillomavirus testing market are Biomedical Diagnostics, Abbott, bioMerieux, CeMines, Gen-Probe, Bio-Rad, Epigenomics, CanAG Diagnostics, Fujirebio, Guided Therapeutics, Ipsogen, J&J Diagnostics, OncoLab, Hologic, Qiagen, Radient, Pharmaceuticals, Polartechnics, Targeted Diagnostics & Therapeutics, Roche, Sequenom, and Siemens Healthcare.
Key players are adopting different strategies, including creative awareness efforts combined with treatment methods such as vaccination and monoclonal antibodies. Moreover, key players are adopting and adhering to updated cervical screening guidelines to maintain and improve their market position.
Human Papillomavirus Testing Market – Trends and Opportunities
The worldwide human papillomavirus testing market is likely to rise at a rapid pace due to the growing frequency of cervical cancer. Moreover, the rise in the global geriatric female population is also expected to drive the human papillomavirus testing market, owing to the prevalence of co-morbidities in senior females. Human papillomavirus is one of the primary causes of cancer worldwide. Hence, there is an increasing demand for diagnostic innovation to detect human papillomavirus (HPV)-associated malignancy. As a result, increased knowledge about the connection between the human papillomavirus and cervical cancer and an unmet need for precision in diagnostic testing are expected to propel the human papillomavirus testing market.
Moreover, the inability of primary screening tests to detect human papillomavirus due to low sensitivity and false-negative results is projected to positively impact the global human papillomavirus testing market. The existing human papillomavirus vaccine cannot protect the female population from cervical cancer, which is expected to boost market development even among human papillomavirus vaccinated women.
Furthermore, due to a lack of ability and resources, developing nations have significant hurdles in implementing cytology-based screening programs. Cytology-based screening programs necessitate a well-established infrastructure for sample processing and interpretation. Cytology-based screening programs require robust healthcare infrastructure, thorough training, and quality control for efficient outcomes. Conventional cytology screening tests have a medium sensitivity of 44% to 78%; however, HPV DNA testing has a high sensitivity of 66% to 100%. Due to the great sensitivity of the HPV test, screening intervals can be increased, allowing for greater screening coverage in high-risk populations. Moreover, new approaches, such as HPV testing have evolved due to the failure of cytology-based screening programs in low-resource settings.
Request a sample to get extensive insights into the Human Papillomavirus Testing Market
Human Papillomavirus Testing Market – Regional Landscape
The North America human papillomavirus testing market is projected to grow due to the rising prevalence of cancer and the government’s early diagnosis and treatment awareness efforts. Moreover, in the United States, the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) provides free or low-cost breast and cervical cancer screening to women without health insurance. This initiative aims to increase the number of women undergoing screening for cancer.
The Asia Pacific human papillomavirus testing market is likely to experience significant growth due to the rising frequency of cervical cancer and other sexually transmitted illnesses such as chancroid, HSV, and HIV. Moreover, the rise in fatality rates due to human papillomavirus transmission and infection is also one of the factors expected to drive significant growth in the human papillomavirus testing market over the forecast period.
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.
Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.
For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update – https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ
Contact
Rohit Bhisey
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Blog: https://tmrblog.com
Email: sales@transparencymarketresearch.com
